616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors
Garralda E, Patel M, Kim T, Sacher A, Forster M, Santoro A, Desai J, Paz-Ares L, Gonzalez A, De Miguel M, Bowyer S, Dziadziuszko R, Kim S, Han S, Krebs M, Lorusso P, Cosman R, Chang J, Jun T, Miller W. 616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors. Annals Of Oncology 2024, 35: s494. DOI: 10.1016/j.annonc.2024.08.683.Peer-Reviewed Original ResearchLong-term follow-upSolid tumors